WallStreetZenWallStreetZen

NASDAQ: REGN
Regeneron Pharmaceuticals Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Regeneron Pharmaceuticals revenue was $14.20B for the trailing 12 months ending Dec 31, 2024, with 10.4% growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $3.8B, up 1.8% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, REGN annual revenue was $14.2B, with 8.3% growth year-over-year.

REGN past revenue growth

How has REGN's revenue growth performed historically?

Company
8.27%
Industry
497.69%
Market
20.68%
REGN's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
REGN's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
REGN's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

REGN revenue history

Current Revenue
$14.2B
Current Earnings
$4.4B
Current Profit Margin
31.1%
REGN's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

Be the first to know when REGN announces revenue.

REGN Revenue History By Year

REGN Yearly RevenueREGN RevenueREGN ChangeREGN Revenue Growth
2024-12-31$14.20B$1.08B+8.27%
2023-12-31$13.12B$944.30M+7.76%
2022-12-31$12.17B-$3.90B-24.26%
2021-12-31$16.07B$7.57B+89.14%
2020-12-31$8.50B$1.94B+29.58%
2019-12-31$6.56B$1.41B+27.44%
2018-12-31$5.15B-$726.60M-12.37%
2017-12-31$5.87B$1.01B+20.82%
2016-12-31$4.86B$756.67M+18.44%
2015-12-31$4.10B$1.28B+45.55%
2014-12-31$2.82B$714.81M+33.96%
2013-12-31$2.10B$726.27M+52.69%
2012-12-31$1.38B$932.65M+209.20%
2011-12-31$445.82M-$13.25M-2.89%
2010-12-31$459.07M$79.81M+21.04%
2009-12-31$379.27M$140.81M+59.05%
2008-12-31$238.46M$113.43M+90.73%
2007-12-31$125.02M$61.58M+97.05%
2006-12-31$63.45M-$2.75M-4.15%
2005-12-31$66.19M-$107.82M-61.96%
2004-12-31$174.02M$116.52M+202.65%
2003-12-31$57.50M$35.51M+161.49%
2002-12-31$21.99M$15.00k+0.07%
2001-12-31$21.97M-$37.30M-62.93%
2000-12-31$59.28M$24.78M+71.82%
1999-12-31$34.50M-$3.83M-9.99%
1998-12-31$38.33M$5.23M+15.79%
1997-12-31$33.10M$8.99M+37.26%
1996-12-31$24.11M-$3.27M-11.94%
1995-12-31$27.38M$4.19M+18.08%
1994-12-31$23.19MN/AN/A

1 of 3

Regeneron Pharmaceuticals Revenue FAQ

What was REGN's revenue last quarter?

On Invalid Date, Regeneron Pharmaceuticals (NASDAQ: REGN) reported Q4 2024 revenue of $3.79 billion up 10.33% year over year. In the same quarter last year, Regeneron Pharmaceuticals's revenue was $3.43 billion.

What was Regeneron Pharmaceuticals's revenue in 2024?

Regeneron Pharmaceuticals's annual revenue for the twelve months ending Dec 31, 2024 was $14.20 billion, a 8.27% increase year over year.

How much does Regeneron Pharmaceuticals make in a day?

Based on Regeneron Pharmaceuticals annual revenue for the past five years, REGN makes an average of $35,101,863.01 per day.

What was Regeneron Pharmaceuticals's annual revenue growth in the past year?

As of Q2 2025, Regeneron Pharmaceuticals's revenue has grown 8.27% year over year. This is 489.42 percentage points lower than the US Biotechnology industry revenue growth rate of 497.69%. Regeneron Pharmaceuticals's revenue in the past year totaled $14.20 billion.

How much does Regeneron Pharmaceuticals make in a year?

Regeneron Pharmaceuticals's revenue by year for the past five years is:
  • Regeneron Pharmaceuticals's revenue for the twelve months ending Dec 31, 2024 was $14.20 billion, a 8.27% increase year over year.
  • Regeneron Pharmaceuticals's annual revenue for Dec 31, 2023 was $13.12 billion, a 7.76% increase from 2022.
  • Regeneron Pharmaceuticals's annual revenue for 2022 was $12.17 billion, a 24.26% decrease from 2021.
  • Regeneron Pharmaceuticals's annual revenue for 2021 was $16.07 billion, a 89.14% increase from 2020.
  • Regeneron Pharmaceuticals's annual revenue for 2020 was $8.50 billion, a 29.58% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.